Nordicus Partners Corp (NORD) is a life sciences holding company that acquires controlling stakes in early-stage biopharmaceutical and biotech businesses with the intent to develop them toward exit. The company's stated model is to scout and accelerate portfolio companies by providing capital, resources, and expertise toward milestones such as patent filings and clinical trials, then exit via sale, merger, further clinical development, strategic pharmaceutical partnerships, or standalone IPO. Nordicus operates through its relationship with NP Bioinnovation A/S, a Danish stock corporation with which it consummated a contribution agreement on February 23, 2023. The company has reported net losses in both fiscal years ended March 31, 2025 and March 31, 2024, with cash flows used in operating activities in both periods. As of the 10-K filed July 29, 2025, Henrik Rouf serves as Chief Executive Officer and Peter Severin serves as Chairman. The company previously held an equity interest in Mag Mile, acquired June 20, 2023 through a Stock Purchase and Sale Agreement with GK Partners.

Revenue model

Nordicus has not disclosed product or service revenue in the filing excerpts. The company generated proceeds from warrant exercises by GK Partners ($576,000 for the fiscal year ended March 31, 2025 at $10.00 per share) and from capital raises through portfolio entity Orocidin. The company reported net losses in both fiscal years ended March 31, 2025 and March 31, 2024.

Products and services

Nordicus targets early-stage biopharmaceutical and biotech companies, providing capital and resources toward clinical milestones and patent filings. Portfolio activities include work through NP Bioinnovation A/S (formerly Nordicus Partners A/S), a Danish stock corporation. The company previously held an interest in Mag Mile. Orocidin is referenced as a portfolio entity that conducted a capital raise as of fiscal year ended March 31, 2025.

Customers and end markets

End markets are early-stage biopharmaceutical and biotech development. The company targets portfolio companies for eventual exit to large pharmaceutical strategic partners, public markets via IPO, or acquirers. No external customer revenue is disclosed in the filing excerpts.

Value-chain role

Early-stage life sciences investor and holding company. Acquires controlling stakes in portfolio companies, funds clinical and patent development milestones, and targets exits via sale, merger, pharma partnership, or IPO.

Geographic exposure

Operations span the United States and Denmark. NP Bioinnovation A/S is a Danish stock corporation. Executive addresses listed in Los Angeles and Beverly Hills, California, and Charlottenlund and Dronningmoelle, Denmark (as of 10-K filed July 29, 2025).

Source: SEC 10-K, filed 2025-07-29

Industry: Services-Management Consulting Services